As part of Medicare Part D changes resulting from provisions in the Inflation Reduction Act (IRA), Independence Blue Cross (IBX) has identified the top five drugs (by volume) that are impacted by these changes. These five drugs are no longer covered, moving to Non-Formulary effective January 1, 2025.
Preferred alternatives are listed below. We recognize that drug selection and prescriptive authority rests with the licensed and treating health care provider.
cyclosporine ophthalmic emulsion 0.05 %
| Restasis® ophthalmic emulsion 0.05 % (brand)
|
Levemir®
| Lantus®, Basaglar®, Toujeo®
Levemir FlexPen and vial were discontinued by the manufacturer as of 12/31/2024.
|
moxifloxacin ophthalmic solution 0.5 %
| ciprofloxacin ophthalmic solution 0.3 % ofloxacin ophthalmic solution 0.3 %
|
lansoprazole
| omeprazole
esomeprazole
pantoprazole
Omeprazole and esomeprazole are also available OTC and can be purchased using the IBX Care Card OTC Benefit
|
diphenoxylate-atropine oral 2.5-0.025 mg
| loperamide oral capsule 2 mg
Also available OTC and can be purchased using the IBX Care Card OTC Benefit
|
You can view the full IBX prescription drug list.
You can also review the IBX Care Card OTC benefit for IBX members.
For more information about the IRA and Medicare Part D changes, please visit the Pharmacy and IRA resource page.
24-0223